Close
Nordic 9Nordic 9

Surveyor Capital (investor - Private Equity)

United States citadel.com
See something wrong or missing? Let us know
Offices:Boston

Surveyor Capital, founded in 2008, is a multi-manager equities strategy, is one of Citadel’s three fundamental equities businesses.

Average round investment:92.32M USD
Average number per year:1.3
Distribution: 2025 (1)2024 (1)2021 (2)
Portfolio companies: Norway ActitheraDenmark AdcendoGermany Emergence Therapeutics See the entire list
Mostly invests in: Norway Norway (1) Biotech (4)
See the entire list

Showing 3 of 4 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Surveyor Capital

Name Criteria
United States Prime Movers Labs
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Pharma, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
Israel Pontifax Venture Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Pharma, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United States Cormorant Asset Management
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Pharma, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States OrbiMed Advisors
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Pharma, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States Foresite Capital
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Pharma, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Netherlands Gilde Healthcare
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Pharma, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United States Venrock Healthcare Capital Partners
81%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Pharma, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany Wachstumsfonds Bayern
81%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Abingworth
81%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Pharma, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States venBio Partners
81%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Pharma, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top